No cost · No obligation
Start with your health question
Share your symptoms and medical history for clinician review. The clinician decides whether any treatment is appropriate.
What to bring to the conversation
- The symptom or diagnosis, when it began, how it has changed, and what you hope to improve.
- Prior evaluations, test results, and treatments, including what helped or caused problems.
- Current medicines, supplements, allergies, and relevant medical history.
- Any specific peptide or formulation you read about and the source of that information.
- Questions about evidence, possible harms, follow-up, and established alternatives.
What happens after an assessment?
A licensed provider determines what further evaluation or care is medically appropriate. That may include established treatment, a referral, more information, or no prescription. The HHS interim compounding policy does not establish that any peptide is effective for your condition or available through Thrivelab.
If a compounded product is discussed, the exact substance, route, pharmacy, state eligibility, product quality, policy conditions, availability, and cost must be reviewed separately. An assessment should not be read as an offer to supply a specific peptide.
Questions worth asking
- What diagnosis best explains my symptoms, and are there urgent signs that need in-person care?
- What human evidence supports each option for my particular condition?
- What are the known risks and the major unknowns?
- If a compounded medicine is considered, how are the source, testing, and dispensing pharmacy verified?
- What outcomes and adverse effects would we monitor, and when would we reassess?
Access and cost questions
A search for “peptide therapy online,” “peptide consultation,” or “peptide therapy cost” can make the process sound like a standard checkout. The actual path starts with a health assessment. The clinician determines medical appropriateness, and any proposed product must be checked for policy scope, state eligibility, pharmacy availability, and its full patient-facing price.
Ask what the assessment costs, whether follow-up visits or testing are needed, what a proposed treatment would cost, and what is included. No price or product availability should be assumed from a search result.
Review the research first
Each guide explains the current evidence and safety gaps. The policy guide explains why conditional HHS enforcement discretion is different from FDA approval.
Important information
Compounded drugs are not FDA approved and have not undergone FDA review for safety, effectiveness, or quality before marketing. HHS's interim policy is conditional and may be revised. Treatment through Jonathan Larson MDPC requires a licensed clinician's evaluation. This page is informational, not medical advice.
Read the HHS policy ↗